Market for pre-filled syringes is expected to account for over $3.2 Billion in revenue by the end of 2015
- Written by Debora White
The Pre-Filled Syringes Market: 2015-2030-Opportunities, Challenges, Strategies & Forecasts is a new market research publication announced by Reportstack. "A pre-filled syringe is a medical syringe that comes pre-filled with a specific dosage of medication. Representing one of the fastest growing segments of the injectable drug delivery ecosystem, pre-filled syringes offer significant benefits over the traditional ‘vial and syringe’ format, by increasing dosing accuracy, safety and convenience.
In addition, pre-filled syringes also offer a variety of economic benefits to pharmaceutical companies including a reduction in drug overfill and waste, which increases the saleable yield of the API (Active Pharmaceutical Ingredient).
It is estimated that the market for pre-filled syringes will account for over $3.2 Billion in revenue by the end of 2015. Despite challenges relating to drug stability, manufacturing and competition from other drug delivery technologies, the market is poised for significant growth in the coming years. Expected to grow at a CAGR of 13% between 2015 and 2020, the market will account for nearly $6 Billion in revenue by the end of 2020.
The “Pre-Filled Syringes Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the pre-filled syringes ecosystem including technology, market drivers, challenges, investment potential, leading therapies, use cases, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for pre-filled syringe unit sales from 2015 through to 2030. The forecasts are further segmented for 4 horizontal submarkets, 10 drug classes, 5 regions and 13 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
"Key Findings:
The report has the following key findings:
- It is estimated that the market for pre-filled syringes will account for over $3.2 Billion in revenue by the end of 2015. Expected to grow at a CAGR of 13% between 2015 and 2020, the market will account for nearly $6 Billion in revenue by the end of 2020
- Many pre-filled syringe manufacturers now also offer integrated automatic needle shielding or retractable needle options
- While glass continues to remain the gold standard for pre-filled syringes, the proportion of plastic based pre-filled syringes is expected to increase by 5% between 2015 and 2020, due to concerns of glass breakage and plunger failure
- A number of pre-filled syringe manufacturers have developed dual and multi chambered syringes, to cater for drugs that must be reconstituted at the point of delivery
- Pre-filled pen systems and auto-injectors will grow at a CAGR of more than 20% over the next five years
Topics Covered:
The report covers the following topics:
- Pre-filled syringes ecosystem
- Market drivers and barriers
- Technology, safety mechanisms and key trends
- Pen systems and auto-injectors
- Industry roadmap and value chain
- Analysis of leading drug classes and pre-filled syringe therapies
- Profiles and strategies of 55 leading ecosystem players, including manufacturers and pharmaceutical giants
- Strategic recommendations for ecosystem players
- Market analysis and forecasts from 2015 till 2030
In addition, pre-filled syringes also offer a variety of economic benefits to pharmaceutical companies including a reduction in drug overfill and waste, which increases the saleable yield of the API (Active Pharmaceutical Ingredient).
It is estimated that the market for pre-filled syringes will account for over $3.2 Billion in revenue by the end of 2015. Despite challenges relating to drug stability, manufacturing and competition from other drug delivery technologies, the market is poised for significant growth in the coming years. Expected to grow at a CAGR of 13% between 2015 and 2020, the market will account for nearly $6 Billion in revenue by the end of 2020.
The “Pre-Filled Syringes Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the pre-filled syringes ecosystem including technology, market drivers, challenges, investment potential, leading therapies, use cases, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for pre-filled syringe unit sales from 2015 through to 2030. The forecasts are further segmented for 4 horizontal submarkets, 10 drug classes, 5 regions and 13 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
"Key Findings:
The report has the following key findings:
- It is estimated that the market for pre-filled syringes will account for over $3.2 Billion in revenue by the end of 2015. Expected to grow at a CAGR of 13% between 2015 and 2020, the market will account for nearly $6 Billion in revenue by the end of 2020
- Many pre-filled syringe manufacturers now also offer integrated automatic needle shielding or retractable needle options
- While glass continues to remain the gold standard for pre-filled syringes, the proportion of plastic based pre-filled syringes is expected to increase by 5% between 2015 and 2020, due to concerns of glass breakage and plunger failure
- A number of pre-filled syringe manufacturers have developed dual and multi chambered syringes, to cater for drugs that must be reconstituted at the point of delivery
- Pre-filled pen systems and auto-injectors will grow at a CAGR of more than 20% over the next five years
Topics Covered:
The report covers the following topics:
- Pre-filled syringes ecosystem
- Market drivers and barriers
- Technology, safety mechanisms and key trends
- Pen systems and auto-injectors
- Industry roadmap and value chain
- Analysis of leading drug classes and pre-filled syringe therapies
- Profiles and strategies of 55 leading ecosystem players, including manufacturers and pharmaceutical giants
- Strategic recommendations for ecosystem players
- Market analysis and forecasts from 2015 till 2030
Companies Mentioned
"Abbott Laboratories
Amgen
AMRI (Albany Molecular Research, Inc.)
Aptar Stelmi
AptarGroup
Artemes Technologies
AstraZeneca
Battelle
Baxter International (Baxter BioPharma Solutions)
BD (Becton, Dickinson and Company)
Bespak
Biocon
Bioneer
Boehringer Ingelheim
BSM (Bristol-Myers Squibb)
Catalent Pharma Solutions
Chugai Pharmaceuticals
Coldstream Laboratories
Consort Medical
Covidien
Daiko Seiko
Dätwyler Holding
Elcam Medical
Eli Lilly and Company
FDA (U.S. Food and Drug Administration)
Fischer Clinical Services
Genentech
Gerresheimer
GSK (GlaxoSmithKline)
Haselmeier
Hospira
Hyaluron
Janssen Biotech
Janssen Research & Development
Johnson & Johnson
Laboratorios Farmacéuticos ROVI
Liebmann Group
LTI (Lyophilization Technology, Inc.)
Medilet
MedPro Safety Products
Medtronic
Merck and Co.
MGlas
Nipro Corporation
Novartis International
Novo Nordisk
Ompi (Stevanato Group)
Owen Mumford
PA Consulting
Pfanstiehl
Pfizer
Revolutions Medical Corporation
Roche Holding (F. Hoffmann-La Roche)
Roselabs
Safety Syringes
Sanofi
Schott
SHL Group
Takeda Pharmaceutical Company
Terumo Corporation
Terumo Europe
Teva Pharmaceutical Industries
Unilife Corporation
Ventana
Vetter Pharma (Vetter Pharma-Fertigung GmbH & Co. KG)
Weigao Group (Shandong Weigao Group Medical Polymer Co.)
West Pharmaceutical Services
Ypsomed Holding
Yukon Medical
Zogenix
"Abbott Laboratories
Amgen
AMRI (Albany Molecular Research, Inc.)
Aptar Stelmi
AptarGroup
Artemes Technologies
AstraZeneca
Battelle
Baxter International (Baxter BioPharma Solutions)
BD (Becton, Dickinson and Company)
Bespak
Biocon
Bioneer
Boehringer Ingelheim
BSM (Bristol-Myers Squibb)
Catalent Pharma Solutions
Chugai Pharmaceuticals
Coldstream Laboratories
Consort Medical
Covidien
Daiko Seiko
Dätwyler Holding
Elcam Medical
Eli Lilly and Company
FDA (U.S. Food and Drug Administration)
Fischer Clinical Services
Genentech
Gerresheimer
GSK (GlaxoSmithKline)
Haselmeier
Hospira
Hyaluron
Janssen Biotech
Janssen Research & Development
Johnson & Johnson
Laboratorios Farmacéuticos ROVI
Liebmann Group
LTI (Lyophilization Technology, Inc.)
Medilet
MedPro Safety Products
Medtronic
Merck and Co.
MGlas
Nipro Corporation
Novartis International
Novo Nordisk
Ompi (Stevanato Group)
Owen Mumford
PA Consulting
Pfanstiehl
Pfizer
Revolutions Medical Corporation
Roche Holding (F. Hoffmann-La Roche)
Roselabs
Safety Syringes
Sanofi
Schott
SHL Group
Takeda Pharmaceutical Company
Terumo Corporation
Terumo Europe
Teva Pharmaceutical Industries
Unilife Corporation
Ventana
Vetter Pharma (Vetter Pharma-Fertigung GmbH & Co. KG)
Weigao Group (Shandong Weigao Group Medical Polymer Co.)
West Pharmaceutical Services
Ypsomed Holding
Yukon Medical
Zogenix
Complete report available @ http://www.reportstack.com/product/185621/the-pre-filled-syringes-market-2015-2030-opportunities-challenges-strategies-forecasts.html
Contact:
Debora White
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
Contact:
Debora White
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research